| Authors: |
Parker CC; Royal Marsden NHS Foundation Trust, Sutton, UK; The Institute of Cancer Research, Sutton, UK., Clarke NW; Department of Urology, The Christie and Salford Royal Hospitals, Manchester, UK; The University of Manchester, Manchester, UK., Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK., Petersen PM; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Catton CN; Department of Radiation Oncology, Princess Margaret, Cancer Centre, University Health Network, Toronto, ON, Canada., Cross WR; Department of Urology, St James's University Hospital, Leeds, UK., Kynaston H; Division of Cancer & Genetics, Cardiff University Medical School, Cardiff, UK., Persad RA; Department of Urology, Bristol Urological Institute, Bristol, UK., Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, Canada., Logue J; Christie Hospital, Manchester, UK., Payne H; The Prostate Centre, London, UK., Amos C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK., Bower L; The Institute of Cancer Research, Sutton, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Raman R; Kent Oncology Centre, Kent & Canterbury Hospital, Canterbury, UK., Sayers I; Deanesly Centre, New Cross Hospital, Wolverhampton, UK., Worlding J; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK. Electronic address: m.sydes@ucl.ac.uk. |
